Pediatric neurosurgeon Dr. Jeffrey A. Kline told CNN that President Donald Trump’s announcement that he is ending federal funding for a pediatric neurologists program that helps children with disabilities was “a slap-in-the-face” for pediatric neurologies in general and for the U.S. overall.
“If we’re going to have a pediatric neurosurgery program, there’s got to be a certain level of funding that goes to pediatric neurologics,” Kline said.
And we should be asking the President why he’s doing it. “
I think that’s just an outrageous claim that’s outrageous.
And we should be asking the President why he’s doing it.
I think he has a responsibility to explain that.”
Trump has called pediatric neurologisn’t a ‘very high priority’ for the federal government and has proposed cutting $200 million from the pediatric neurologys programs that support millions of children and adults in underserved areas.
The President has also proposed ending funding for pediatric neuropathology centers in urban areas, which are often less well-served by Medicaid funding.
Kline said that Trump’s statement that he’s cutting funding for the pediatric neurosurgical programs that are a part of the National Center for Traumatic Stress, which is administered by the Centers for Disease Control and Prevention, was not accurate.
“I would think that the National Institutes of Health would be looking at the cost of that program,” Klink said.
“The fact is, the $200 billion the NIH spends on the National Traumatic Brain Injury Center is more than the CDC spends on its own research on PTSD,” he said.
Klink also said that he did not think the Trump administration’s decision would have any effect on the funding for local pediatric neurologic centers.
The Trump administration said in a statement that it was “reviewing the President’s statement regarding funding for NCTS.”
The National Center For Traumatic Stress, or NCTST, is administered jointly by the CDC and the U,S.
Department of Health and Human Services.
The NCTSP has been operating in the United States since 2010, but its funding is capped at $200,000 annually.
The funding was expanded in 2015 to include funding for clinical trials.